Vietnam officially launched Phase 3 trials for homegrown Covid-19 vaccine Nanocovax

Thứ Sáu, 11/6/2021| 16:28

Vietnam’s Ministry of Health on Friday authorized Phase 3 clinical tests to be carried out on volunteers for the Nanocovax vaccine developed by Nanogen Company.

The tests for the two-shot vaccine were authorized for more than 10,000 volunteers, aged 18 and over, in many Vietnam’s provinces and cities.

Nanocovax is the Covid-19 vaccine candidate researched and developed by Ho Chi Minh City-based Biopharmaceutical Company Nanogen, based on recombinant DNA/protein technology.

After having accomplished the pre-clinical trial with high safety and efficacy, Nanocovax was approved by Vietnam’s Ministry of Health to conduct clinical trial in Vietnam.

 

Vietnam officially launched Phase 3 trials for homegrown Covid-19 vaccine Nanocovax

Nanocovax is the most potential Covid-19 vaccine candidate in Vietnam.

Phase 1 of the clinical trial started on December 2020. In Phase 2, the Nanocovax vaccine was tested for 554 volunteers, including 109 people over 60 years old.

Nanocovax developed by Nanogen Company is the most potential Covid-19 vaccine candidate in Vietnam, followed by IVAC's Covivac vaccine preparing for phase 2 trials.

Nanogen's current capacity is about 6 million doses per month and can be increased to 100 million doses per year.

Top